Jim Cramer - Mad Money Veru VERU-Q DON'T BUY Oct 17, 2022

It was the biggest gainer in biotech today, this little-known name which soared 52.56% today. This drugmaker focuses on oncology and urology. It's tripled in the past week. They just produced promising phase 2 clinical trial data for their drugs treating breast cancer, and more positive data for prostate cancer. He doesn't chase stocks after a big run, but positive trial data spells a promising stock.

It soared 28% today off great Covid drug data. They've been developing treatments for breast and prostate cancers. A few months ago, the stock tripled on stage 2 clinical trial data for their breast cancer therapy. Earlier this year, they started studying one of their cancer drugs to treat acute respiratory distress caused by severe Covid. This drug showed an 82% in deaths. Phase 3 results will likely come in Q4.

It's come down a lot--too much, but boasts some fine drugs. A crazy trading stock, but he believes in it.

Their prostate cancer drug is real. For $8/share, you're in good shape.

Their breast cancer treatment just got fast-tracked by the FDA today. And yet, shares fell $5. This makes no sense. This should have risen.